Response to ibrutinib in chronic lymphocytic leukemia improves in quality with time

Unlike chemoimmunotherapy regimens, which are given for a defined period, ibrutinib, a first‐in‐class Bruton's kinase inhibitor, allows most patients with CLL to remain on treatment for an extended period. Our experience, supported by sequential CT scan images, suggests that long‐term ibrutinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Molica, Stefano, Carillio, Guido, Battaglia, Caterina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Clinical Image
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5224778/
https://www.ncbi.nlm.nih.gov/pubmed/28096995
http://dx.doi.org/10.1002/ccr3.749
_version_ 1782493419274240000
author Molica, Stefano
Carillio, Guido
Battaglia, Caterina
author_facet Molica, Stefano
Carillio, Guido
Battaglia, Caterina
author_sort Molica, Stefano
collection PubMed
description Unlike chemoimmunotherapy regimens, which are given for a defined period, ibrutinib, a first‐in‐class Bruton's kinase inhibitor, allows most patients with CLL to remain on treatment for an extended period. Our experience, supported by sequential CT scan images, suggests that long‐term ibrutinib promotes a high response rate that improves in quality with time.
format Online
Article
Text
id pubmed-5224778
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-52247782017-01-17 Response to ibrutinib in chronic lymphocytic leukemia improves in quality with time Molica, Stefano Carillio, Guido Battaglia, Caterina Clin Case Rep Clinical Image Unlike chemoimmunotherapy regimens, which are given for a defined period, ibrutinib, a first‐in‐class Bruton's kinase inhibitor, allows most patients with CLL to remain on treatment for an extended period. Our experience, supported by sequential CT scan images, suggests that long‐term ibrutinib promotes a high response rate that improves in quality with time. John Wiley and Sons Inc. 2016-12-01 /pmc/articles/PMC5224778/ /pubmed/28096995 http://dx.doi.org/10.1002/ccr3.749 Text en © 2016 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Clinical Image
Molica, Stefano
Carillio, Guido
Battaglia, Caterina
Response to ibrutinib in chronic lymphocytic leukemia improves in quality with time
title Response to ibrutinib in chronic lymphocytic leukemia improves in quality with time
title_full Response to ibrutinib in chronic lymphocytic leukemia improves in quality with time
title_fullStr Response to ibrutinib in chronic lymphocytic leukemia improves in quality with time
title_full_unstemmed Response to ibrutinib in chronic lymphocytic leukemia improves in quality with time
title_short Response to ibrutinib in chronic lymphocytic leukemia improves in quality with time
title_sort response to ibrutinib in chronic lymphocytic leukemia improves in quality with time
topic Clinical Image
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5224778/
https://www.ncbi.nlm.nih.gov/pubmed/28096995
http://dx.doi.org/10.1002/ccr3.749
work_keys_str_mv AT molicastefano responsetoibrutinibinchroniclymphocyticleukemiaimprovesinqualitywithtime
AT carillioguido responsetoibrutinibinchroniclymphocyticleukemiaimprovesinqualitywithtime
AT battagliacaterina responsetoibrutinibinchroniclymphocyticleukemiaimprovesinqualitywithtime

Ejemplares similares